Nabi Biopharmaceuticals said its StaphVax vaccine, for preventing staph infections among kidney disease patients, failed to meet its goals in a Phase III trial, so the company will withdraw its application for EU approval. Nabi also said it will stop developing its Altastaph, a treatment based on the StaphVax technology, but will continue developing drugs related to smoking cessation and hepatitis C.

Related Summaries